How did Reviva's operating expenses trend in Q3 2024?

Reviva Pharmaceuticals' operating expenses for Q3 2024 are not currently available. However, the company's financial results for Q2 2024 are reported, which may provide some insight into the company's spending trends.

1. **Financial Results for Q2 2024**: Reviva Pharmaceuticals reported earnings per share (EPS) of -$0.26 for Q2 2024, which was above the analyst estimate of -$0.29. The company did not report any revenue for the quarter.
2. **Operating Expenses in Q2 2024**: Reviva Pharmaceuticals reported research and development expenses of $5,584,347 for Q2 2024. This indicates that the company's spending was focused on advancing its drug development pipeline, particularly for brilaroxazine.
3. **Trends and Context**: The absence of Q3 2024 operating expenses data makes it difficult to directly analyze trends from Q2 2024. However, the company's emphasis on drug development, as indicated by the reported R&D expenses, suggests that operating expenses are likely to be significant, at least in relation to the company's revenue generation at this stage.

In conclusion, while specific Q3 2024 operating expenses are not available, the available data from Q2 2024 indicates that Reviva Pharmaceuticals' expenses are primarily focused on research and development, which is a critical component of the company's growth and potential future revenue streams.